Form 4: Arvinas Director Everett Cunningham Receives Significant Equity Grants

Arvinas, Inc. Director Everett Cunningham was granted 16,025 Restricted Stock Units and 23,105 Stock Options on June 25, 2025, as part of his compensation.

Summary

• Everett Cunningham, a Director of Arvinas, Inc. (ARVN), received equity grants on June 25, 2025.
• The grants include 16,025 Restricted Stock Units (RSUs) and 23,105 Stock Options.
• The RSUs represent a contingent right to receive one share of common stock for no consideration.
• The Stock Options have an exercise price of $7.8 per share.
• Both the RSUs and Stock Options will vest in full on the earlier of June 25, 2026, or the first meeting of the board of directors after the following annual meeting of stockholders, subject to continued service.
• Following these transactions, Mr. Cunningham beneficially owns 26,045 shares of common stock (including RSUs) and 23,105 stock options.

Sentiment

Score: 7

Explanation: The grant of equity to a director is a positive event as it aligns their interests with shareholders and is a standard compensation practice, indicating stability in governance.

Positives

• The grant of equity to a director aligns their interests with those of the shareholders, incentivizing long-term performance.
• Equity compensation is a common and effective way to attract and retain key personnel.

Risks

• The vesting of both Restricted Stock Units and stock options is contingent upon Mr. Cunningham's continued service with Arvinas, Inc. on the vesting date.

Future Outlook

The vesting schedule for the granted RSUs and stock options indicates an expectation of continued service from Director Everett Cunningham through at least June 25, 2026, or until the first board meeting after the next annual stockholders' meeting.

Industry Context

The granting of equity compensation, including Restricted Stock Units and stock options, to non-employee directors is a standard practice across various industries, particularly in biotechnology and pharmaceutical sectors like Arvinas, Inc. This method is widely used to attract, retain, and incentivize directors by aligning their financial interests with the long-term performance of the company and its shareholders.

Comparison to Industry Standards

• Equity grants to directors are a common form of compensation in the biotech industry, similar to practices at companies like Moderna, BioNTech, or Gilead Sciences, where a significant portion of director compensation is often equity-based to foster alignment with shareholder value.
• The specific number of units granted (16,025 RSUs and 23,105 options) and the vesting schedule (one year or next annual meeting) are generally within the range of typical director compensation packages for companies of similar market capitalization and stage of development, though exact comparisons would require detailed analysis of peer proxy statements.

Stakeholder Impact

• Shareholders: Positive impact as director's interests are further aligned with shareholder value through equity ownership.

Next Steps

• Vesting of the 16,025 Restricted Stock Units on the earlier of June 25, 2026, or the first board meeting after the next annual stockholders' meeting.
• Vesting of the 23,105 Stock Options on the earlier of June 25, 2026, or the first board meeting after the next annual stockholders' meeting.

Key Dates

Keywords

Arvinas, ARVN, SEC Form 4, Everett Cunningham, Director, Restricted Stock Units, RSUs, Stock Options, Equity Grant, Insider Transaction, Compensation, Corporate Governance